[1] Meager A.Biological assays for interferons[J].Journal of Immunological Methods,2002,261(1/2):21-36. [2] Johnson H M,Bazer F W,Szente B E,et al.How interferons fight disease[J].Scientific American,1994,270(5):68-75. [3] Sekellick M J,Ferrandino A F,Hopkins D A,et al.Chicken interferon gene:Cloning,expression,and analysis[J].Journal of Interferon Research,1994,14:71-79. [4] 程福亮,聂兆晶,陈甜甜,等.重组鸡α-干扰素的表达及其生物活性的初步研究[J].中国畜牧兽医,2014,41(11):35-39. [5] 刘成倩,王 静,李 红,等.鸡干扰素-α基因原核表达载体的构建及高效表达[J].中国畜牧兽医,2014,41(4):47-50. [6] Liao W J,Lin X,Leonard W J.Interleukin-2 at the crossroads of effector responses,tolerance,and immunotherapy[J].Immunity,2013,38(1):13-25. [7] Taguchi T.Interleukin-2 (IL-2)[J].Gan To Kagaku Ryoho,1994,21(5):719-724. [8] Robak T.Biological properties and therapeutic use of interleukin 2 (IL-2)[J].Postepy Higieny Medycyny Doswiadczalnej,1995,49(3):367-393. [9] Prentice H G,Macdonald I D,Hamon M D.The role of immunotherapy in the treatment of acute myeloblastic leukemia:From allogeneic bone marrow transplantation to the application of interleukin 2[J].Cancer Treatment and Research,1993,64:121-134. [10] 闫若潜,谢彩华,吴志明,等.鸡α干扰素/白细胞介素2基因的融合表达及活性研究[J].中国农业科学,2010,43(3):594-604. [11] Zamoiskii E A.Evaluation of Reed-Muench method in determination of activity of biological preparations[J].Zhurnal Mikrobiology Epidemiology Immunobiology,1956,27(1):77-83. [12] 闫若潜,吴志明,张志凌,等.猪α干扰素/白细胞介素2基因的融合表达及活性研究[J].畜牧兽医学报,2009,40(2):248-255. [13] Legha S S.Durable complete responses in metastatic melanoma treated with interleukin-2 in combination with interferon alpha and chemotherapy[J].Semin Oncol,1997,24(1 Suppl 4):S39-S43. [14] Lefèvre F,L'Haridon R,Borras-Cuesta F,et al.Production,purification and biological properties of an Escherichia coli-derived recombinant porcine alpha interferon[J].Clinical and Diagnostic Laboratory Immunology,1990,71(5):1057-1063. [15] Oldham R R.Toxic effects of interferon[J].Science,1983,219(4587):902. |